Louise Madden

Nuisance compounds are known to interfere with bioassay readouts in High Throughput Screening (HTS), often leading to false positives. At Enamine, we offer a curated set of 83 useful nuisance compounds, conveniently formatted in an assay-ready plate, to support the development of valid screening assays. Our set helps researchers identify potential assay interferences early, leading to more reliable and actionable HTS results. This collection includes PAINS (Pan-Assay Interference Compounds), colloidal aggregates, electrophiles, redox cyclers, chelators, and other assay-interfering chemotypes. Learn more: https://lnkd.in/di7Hfzz4

138

We’re pleased to announce the commercial availability of GENE-UP® PRO HRM - the first DNA-based test commercially developed to detect heat-resistant molds at the molecular level. 🧬 Developed in partnership with historic brand Ocean Spray Cranberries , this game-changing assay can accurately identify the presence of viable heat-resistant molds with a validated equivalency to the CMMEF Ch22 Reference Method. ✅ GENE-UP® PRO HRM also provides a significantly shorter time-to-result, reducing the current Compendial Method 15-day result time down to only 3 days. 📰 Read the full press release on our website for more information: http://spkl.io/6044AJLjo

161

4 Comments

Manual peak picking of multi-dimensional NMR spectra is a thing of the past. NMRtist employs a neural network trained on curated datasets to automate peak picking, saving you valuable time and reducing human error. Whether you're working with three- or four-dimensional protein spectra, NMRtist streamlines the initial step of your analysis, allowing you to focus on what truly matters—your research. Explore more: https://lnkd.in/dnuekMWc #Bruker #NMRtist #NMRchat #ProteinAnalysis #StructuralBiology

131

1 Comment

🚀 We'd like to spotlight this new excellent TCE review article. One of major side effects associated with T cell engagers (TCEs) is toxicities related to cytokine release syndrom. One key strategy to mitigating this risk is affinity attenuation of CD3 binding arm, in order to achieve potent tumor cell killing with minimal cytokine secretion. This review article provides an overview of the current state and recent developments in CD3 affinity-attenuation, both preclinically and clinically, with a focus on the challenges of developing TCEs with attenuated affinity to CD3 as well as identifying possible areas of improvement. All the authors of this excellent article entitled “The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?” are from Roche's Pharma Research and Early Development (pRED). They are Omar Abdelmotaleb, Anneliese Schneider, Christian Gassner, Stephan Märsch & Christian Klein. Free access to this paper at: https://lnkd.in/g9_gBZGW We’d like to take this opportunity to bring your attention to call for papers by Antibody Therapeutics in the theme of Cell Therapies and/or Cell Engagers against Cancer. Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI (Impact Factor: 4.5), PubMed and Scopus (CiteScore: 8.4). The deadline for submission is December 31, 2025. For more detailed information, please visit: https://lnkd.in/esh6_s2h #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #tce #tcellengager  #tcellengagers

96

1 Comment

📢 PRESS RELEASE 📢 ARCHIMED acquires cell line development pioneer ExcellGene SA and sister company Magellan Biologics & Consulting to accelerate expansion into biosimilars and high-performance transfection solutions.   Partnering with founders and management, #ARCHIMED aims to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/gi-T5ASm #ARCHIMED #ImpactingHealthcare #ExcellGene #MagellanBiologics #Bioprocessing #Therapeutics

630

13 Comments

We are proud to announce we are now an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). This strategic partnership underpins our commitment to innovation in particle science- helping to shape the future of orally inhaled and nasal drug products. By collaborating with key industry leaders and regulatory bodies, we will support the ongoing development of robust regulatory frameworks that enhance the quality of nasal sprays and inhalers- exceeding expectations for both manufacturers and patients. We are excited to bring our expertise and market-leading technologies to the forefront of regulatory science discussions, including: - Spraytec, for aerosol particle analysis - Morphologi MDRS, for advanced particle characterization and chemical analysis - Zetasizer and Mastersizer, for comprehensive particle size and zeta potential analysis #Pharma #ParticleAnalysis #Aerosols #NasalSprays #OINDP #RegulatoryScience

41

1 Comment

Poor aqueous solubility remains one of the most persistent hurdles in drug development—impacting bioavailability, formulation stability, and ultimately, therapeutic efficacy. In our latest case study, Aragen scientists demonstrate a robust and scalable strategy to develop monodisperse nanosuspension formulations for a poorly soluble drug substance, offering a practical solution to this complex challenge. This study highlights Aragen’s strategic integration of particle engineering and process optimization expertise to achieve monodisperse nanosuspensions with precision and scalability. Discover how advanced particle engineering and process optimization led to:- - Narrow particle size distribution - Enhanced bioavailability - Scalable and reproducible manufacturing Read the full case study : https://lnkd.in/gqVydsw8 #formulation #Drugdevelopment #SolubilityEnhancement #Aragen

60

1 Comment